Mary-Louise Ortiz - Communications Specialist/ Customer
news.cision.com
The company's listed phone number is 781-996-5252 and its investor relations email address is [email protected] The official website for Kala Pharmaceuticals is www.kalarx.com. Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that members of its management team will participate virtually in the following upcoming conferences: Kala Pharmaceuticals to Present at Upcoming Investor Conferences in January. Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for di Kala Pharmaceuticals to Present at Upcoming Investor Conferences in March | Placera Kala Still Has A Shot To Reach Its Goal For Approval After Latest Setback - Kala Pharmaceuticals, Inc. (NASDAQ:KALA) | Seeking Alpha. 2019-08-29 seekingalpha.com - 3 - Kala Pharmaceuticals had received a CRL for its corticosteroid drug known as KPI-121 0.25% for the treatment of dry eye disease. At ANI Pharmaceuticals, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below.
It has a market capitalization of US$445m, which means it wouldn't have the attention of many institutional investors. Taking a look at our data on the ownership groups (below), it seems that institutional investors have bought into the company. Kala Pharmaceuticals, Inc. (Kala) is a clinical-stage pharmaceutical company focused on innovative nanoparticle-based treatments for ocular diseases affecting both front and back of the eye. Kala leverages its proprietary mucus-penetrating particle (MPP) technology to develop topical ophthalmic formulations with enhanced delivery into ocular tissue by facilitating penetration through the tear Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced Investor Relations; Financial Reports. SEC Filings; Annual Reports; Quarterly & Other Reports; Events & Presentations; Stock Information; Corporate Governance. Policies; Executive Officers & Directors; Board Committees; Investor Resources.
news.cision.com
Our decades of proven success come from a global team of passionate employees collaborating to bring the best treatments forward. Xenon Pharmaceuticals Inc. 3650 Gilmore Way Burnaby, BC V5G 4W8.
Webbkarta - IG
Feb 25, 2021. ©2020 Kala Pharmaceuticals All rights reserved. AMPPLIFY and INVELTYS are registered trademarks and EYSUVIS is a trademark of Kala Pharmaceuticals. US-EYS-2000035 November 2020 This page shows the institutions and funds most likely to invest in KALA / Kala Pharmaceuticals, Inc., based on analysis of their current holdings.
The Investor Relations website contains information about Kala Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. The Investor Relations website contains information about Kala Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. Cash Position: As of June 30, 2020, Kala had cash, cash equivalents and short-term investments of $184.6 million, compared to $85.4 million as of December 31, 2019. Company Name: Kala Pharmaceuticals, Stock Symbol: KALA, Industry: Biotechs, Total Posts: 65, Last Post: 4/12/2021 11:08:08 AM
Dr. Kameswaran has served as our Senior Vice President, Strategy since January 2020, leading the Business Development and Investor Relations functions. Prior to that, he served as Vice President, Strategy from June 2018 to January 2020, and as Director, Commercial and Business Development from April 2017 to June 2018.
Svensk förvaltningsstyrning
Som Chauhan's colleagues are Mohd Ziya, Shivani Kala, John Anderson, Surbhi Gupta. See more information about Som CARMEL PHARMA. 22,7. 7.
E-mail Alerts. You may automatically receive Kala Pharmaceuticals, Inc. financial information by e-mail.Please enter your e-mail address below and click Submit. Dr. Kameswaran has served as our Senior Vice President, Strategy since January 2020, leading the Business Development and Investor Relations functions. Prior to that, he served as Vice President, Strategy from June 2018 to January 2020, and as Director, Commercial and Business Development from April 2017 to June 2018. Every investor in Kala Pharmaceuticals, Inc. (NASDAQ:KALA) should be aware of the most powerful shareholder groups.Insiders often own a large chunk of younger, smaller, companies while huge
2021-03-02 · Kala Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management
The Investor Relations website contains information about KalVista Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.
Glassbilen gavle
Start a 14-day free trial to Morningstar Premium to unlock our take on KALA. Who We Are · Work H 2 Mar 2021 Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical recording of each presentation, please visit "Events" in the "Investors" View Kala Pharmaceuticals (www.kalarx.com) location in Massachusetts, United Kala Pharmaceuticals to Present at Upcoming Investor Conferences in March 2021 Pre-recorded presentation will be made available beginning Tuesday, . Kala Pharmaceuticals develops novel treatments for diseases that affect Number of Investors 14 Stock Symbol NASDAQ:KALA; Company Type For Profit. 2 Mar 2021 Kala Pharmaceuticals to Present at Upcoming Investor Conferences in March Pre-recorded presentation will be made available beginning Kala Pharmaceuticals stock investors activity. KALA Stock investors sentiment based on 381013 active investor portfolios. View the investor activity. The Director of Investor Relations and Corporate Communications will be responsible for ensuring the company is appropriately and strategically positioned with 15 Feb 2021 With a market capitalization of US$484m, Kala Pharmaceuticals is a small cap This may not be consistent with full year annual report figures.
Corporate Presentation March 2021 2.4 MB. Investor Tools. Kala Pharmaceuticals to Present at Upcoming Investor Conferences in January (Businesswire) 2021-01-04 14:00 Mark Iwicki, Chairman and Chief Executive Officer of Kala Pharmaceuticals, is scheduled to present at the 39 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 9:10 a.m.
Malignt neuroleptikasyndrom
Som Chauhan - Associate Vice President - iEnergizer
Big Biotech Investors Poured $29 Million Into 2 Battered Companies. Oct. 12, 2018 at The Investor Relations website contains information about Kala Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. Kala Pharmaceuticals, Inc. 490 Arsenal Way. Watertown Massachusetts 02472.